clinical trial · NCT06517875
Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
GlaxoSmithKline·phase2·recruiting·n = 68
Primary MyelofibrosisMyelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia MyelofibrosisMomelotinibLuspatercept
brief summary
The purpose of this Phase 2 study is to evaluate the efficacy and safety of momelotinib (MMB) in combination with luspatercept (LUSPA) in participants with transfusion dependence (TD) primary myelofibrosis (PMF) or Post-polycythemia vera (PV)/ essential thrombocythemia (ET) myelofibrosis (MF) who are either janus kinase (JAK) inhibitor (JAKi) naïve or experienced.
started
Feb 28, 2025
primary completion
Mar 19, 2027
completion
Mar 17, 2028
last updated
Apr 20, 2026
official title
A Phase 2 Open-label Study to Evaluate Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Primary or Secondary Myelofibrosis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol